FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kezar Life Sciences Inc. Announces Interim Results from the MISSION Phase 2 Trial”
Kezar Life Sciences Inc. (NASDAQ: KZR) surged over 42% in premarket trading after the company reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616.
The company’s candidate demonstrated clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response at end of treatment.
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis.
For more information, please visit: Kezar Life Sciences Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post “The Buzz” Show: Kezar Life Sciences Inc. (NASDAQ: KZR) MISSION Phase 2 Trial first appeared on Financial Buzz .
For further details see:
“The Buzz” Show: Kezar Life Sciences Inc. (NASDAQ: KZR) MISSION Phase 2 Trial